3 Mid-Year Mid-Cap Biotech Picks
“All three picks can be volatile but very tradable and should be considered as long term holds with expectations for growth, positive clinical data or M&A.”
“All three picks can be volatile but very tradable and should be considered as long term holds with expectations for growth, positive clinical data or M&A.”
Tech companies involved in software, AI and e-commerce, and a medical device company that designs innovative injection technologies, are among the new stocks to watch.
When it comes to the future of the biotech industry, the author of today’s article notes that “the aging population ensures that demand for new… Read More »A Trio Of Top Biotech Stock Picks
With a potential $5+ billion drug that could ultimately be used against dozens of diseases, the clinical-stage biotech company discussed in today’s article “is a ripe acquisition target, and when that acquisition comes, it will go for a steep price.”
Shares of the relatively unknown biopharmaceutical company discussed in today’s article have experienced extreme volatility this month, hitting their all-time low on June 2nd before proceeding to soar to their all-time high on June 10th.
Perceptive Life Sciences, a fund that has outperformed the market, sold all of its 1 million shares of Novavax in the first few months of 2021 and bought millions more shares of three biopharma/biotech stocks in the same period.
Examining four oncology stocks that could be smart picks right now.
After trailing the broader market for the past few months, biotech has gotten some love in recent days – from the FDA in the form of its approval of Biogen’s controversial Alzheimer’s drug, and also from the Reddit crowd.
Mental health issues are on the rise – and so is demand for treatments for mental health disorders based on psychedelic substances.
As PDUFA dates can serve as catalysts for stocks, biotech investors can be well served by paying attention to them.